DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...
(COLORADO SPRINGS) — FOX21 News has learned alternative ways people are getting around the shortage of the medical device called the Dexcom, a glucose monitor for diabetes. Some diabetics are now ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose monitoring (CGM) market. A strong third-quarter 2025 performance and a series ...
DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...
Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy ...
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again helping establish a new annual observance. Glucose sensor maker Dexcom and ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback